News

More than 35,000 cases of the mosquito-borne disease have been reported on the French Indian Ocean island since August 2024.
More than 35,000 cases of the mosquito-borne disease have been reported on the French Indian Ocean island since August 2024.
Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.
A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...
Outbreaks of vaccine-preventable diseases such as measles, meningitis, and yellow fever are on the rise globally amid ...
The Advisory Committee on Immunization Practices (ACIP) has voted to expand the recommended use of GSK’s AREXVY (Respiratory ...